Yi X, Zhang G, Yuan J
Department of Urology, Xijing Hospital, Xi'an, Shaanxi, China.
Transplant Proc. 2013 Mar;45(2):517-22. doi: 10.1016/j.transproceed.2012.02.051.
Donor preconditioning by fenoldopam is demonstrated to improve graft function in recipients. Involvement of hypoxia-inducible factor-1alpha (HIF-1α) and heme oxygenase-1 (HO-1) in renoprotection after fenoldopam pretreatment was investigated.
Donor Sprague-Dawley (SD) rats were intravenously treated with fenoldopam (5 μg/kg · min), Sch23390 (10 μg/kg · min), or fenoldopam + Sch23390 for 1 hour. Kidneys experiencing 24 hours of cold preservation were transplanted into syngeneic SD recipients. Ten days after transplantion, serum concentrations of creatinine (sCR), blood urea nitrogen (BUN), interleukin (IL)-8, and tumor necrosis factor (TNF)-α in recipient were determined. Grafts were procured for histopathological examination, apoptosis analysis, and measurements of malondialdehyde and total superoxide dismutase activities; meanwhile, both protein level and mRNA level of HIF-1α and HO-1 were assessed.
Fenoldopam preconditioning significantly decreased the serum concentrations of sCR, BUN, IL-8, and TNF-α in recipients. Low apoptosis rate and reduced oxidative stress were found in these grafts. Increased HIF-1α activation and HO-1 expression were observed in fenoldopam pretreatment group. Sch23390 partly inhibited the effects of fenoldopam in the combination group.
Donor preconditioning by fenoldopam exerts renoprotection in grafts, at least in part, through HIF-1α activation and HO-1 expression. This provides a preference for further studies.
已证实使用非诺多泮对供体进行预处理可改善受体的移植肾功能。本研究调查了缺氧诱导因子-1α(HIF-1α)和血红素加氧酶-1(HO-1)在非诺多泮预处理后肾脏保护中的作用。
将供体斯普拉格-道利(SD)大鼠静脉注射非诺多泮(5μg/kg·min)、SCH23390(10μg/kg·min)或非诺多泮+SCH23390,持续1小时。将经历24小时冷保存的肾脏移植到同基因SD受体中。移植后10天,测定受体血清肌酐(sCR)、血尿素氮(BUN)、白细胞介素(IL)-8和肿瘤坏死因子(TNF)-α的浓度。获取移植肾进行组织病理学检查、凋亡分析以及丙二醛和总超氧化物歧化酶活性的测定;同时,评估HIF-1α和HO-1的蛋白水平和mRNA水平。
非诺多泮预处理显著降低了受体血清中sCR、BUN、IL-8和TNF-α的浓度。这些移植肾的凋亡率较低且氧化应激减轻。在非诺多泮预处理组中观察到HIF-激活增加和HO-1表达上调。在联合组中,SCH23390部分抑制了非诺多泮的作用。
非诺多泮对供体进行预处理至少部分通过激活HIF-1α和上调HO-1表达对移植肾发挥肾脏保护作用。这为进一步研究提供了方向。